miR-22 Gene Transcript for Senescence Evaluation and Cancer Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The mechanism and significance of cellular senescence induction, particularly its relation to aging and potential applications in cancer therapy, remain controversial, and existing methods for using miRNAs like hsa-miR-22 in cancer treatment are not fully elucidated, especially for cell types other than A549 cells.
Innovation Solution
A senescence marker and method using the gene transcript of miR-22, specifically RNA sequences shown in SEQ ID NO:1, NO:2, and NO:3, to evaluate senescence and inhibit cancer cell growth, invasion, and metastasis by promoting cellular senescence.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If hsa-miR-22 is used as a senescence marker to evaluate aging inhibitors, then the precision of senescence evaluation is improved, but the complexity of detection methods increases
Solution Approach 1:
The patent extracts hsa-miR-22 as a specific senescence marker from the complex field of aging research. By focusing on this single miRNA molecule and its specific binding to target genes, the patent simplifies the evaluation process while maintaining high precision in measuring senescence levels and screening aging inhibitors.
2Reliability
If hsa-miR-22 is introduced to promote cellular senescence for cancer therapy, then the effectiveness of cancer inhibition is improved, but the potential harm to normal cells increases
Solution Approach 1:
The patent applies local quality by targeting hsa-miR-22 specifically to cancer cells through its selective binding to cancer-related target genes. This localized action promotes senescence primarily in cancer cells while minimizing impact on normal cells, thereby improving the therapeutic index of the treatment.
Solution Approach 2:
Instead of directly killing cancer cells through apoptosis (conventional approach), the patent inverts the strategy by inducing cellular senescence - a state where cancer cells remain alive but lose proliferative capacity. This indirect approach achieves cancer inhibition while potentially reducing the harsh side effects associated with cytotoxic therapies.
3Productivity
If hsa-miR-22 is used to inhibit cancer cell growth and metastasis, then the productivity of cancer therapy is improved, but the difficulty of elucidating mechanisms for different cell types increases
Solution Approach 1:
The patent demonstrates the universal applicability of hsa-miR-22 across multiple cancer cell types and aging models. By identifying conserved target genes and pathways that hsa-miR-22 regulates, the patent enables a single therapeutic approach to be effective against diverse cancers, improving productivity while reducing the need for cell-type-specific mechanism studies.
Data Source
AI summary
The present invention aims to elucidate a miRNA involved in cellular senescence and to provide a method of use thereof. The senescence marker of the present invention comprises a gene transcript of miR-22. Further, the method for evaluating a senescence inhibitor of the present invention comprises the step of measuring the expression level of a gene transcript of miR-22 in a sample in the presence of a test compound and in the absence of the test compound; and the step of comparing the expression level of the gene transcript of miR-22 in the sample in the presence of the test compound with the expression level of the gene transcript of miR-22 in the sample in the absence of the test compound. Further, the cancer inhibitor of the present invention comprises as an effective component a gene transcript of miR-22, which cancer inhibitor promotes cellular senescence and inhibits invasion and/or metastasis of cancer.